The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Good buys appearing.
Sharesoc.
Many thanks for the information trek. I can smell a move by somebody in the future. Crystal globe a bit cloudy at the moment!
Marge......BUYOUT GROUP, INVESTMENT BANKER
Ms. Margarita Krivitski is a Vice President at ValueAct Capital Management LP.
She is on the Board of Directors at Horizon Discovery Group Plc.
Prior to joining ValueAct Capital in September 2015, Ms. Krivitski worked at TPG Capital in the North American Buyout Group. Prior to TPG Capital, Ms. Krivitski worked at Goldman Sachs in the Investment Banking Division.
She received a B.A. in Applied Mathematics from Harvard University.
VA have increased, Woodford and Invesco have reduced. SP has stayed in an albeit wide trading range but has ticked up of late as those Invesco sells has shifted. I wonder if VA have picked up more. Remember Margarita Krivitski joined the board as Non-Executive Director and works for VA. This is her statement. “I look forward to working closely with the Board and management team as they execute their strategic plan and drive long term value creation for all stakeholders." I am of the opinion that VA want to really capitalise on their investment in HZD, that means massive turnaround in performance or else they have the fire power to support any bid. I think it’s going to be an interesting day Monday. Just wonder how good Marge is at her NED role. Trek, usual caveats apply.
Will be interesting to see who has bought Invesco share. Although Invesco still have retained 4.44%. Looking verrrrry
Interesting.
Yep I think our new CFO has teed it up nicely and expect more buying tomorrow as traders have a nibble. Trek
Expect deharmacon to have a significant impact on results. Plus horizon numbers should be good.
Copied from OPTI board (I hold OPTI) care of Primal123
uk.finance.yahoo.com/news/3-under-radar-healthcare-stocks-072834051.html?guccounter=2
Transitioning to profitability
Horizon Discovery (LSE: HZD) is listed on London’s junior AIM market. At a share price of 173p, its market capitalisation is £260m.
It’s a global leader in the design, manufacture and application of gene editing and gene modulation technologies. Its products and services are used by researchers and drug developers, and it counts major pharmaceutical companies, including AstraZeneca, among its customers.
Horizon has been building scale and is currently loss-making. However, it’s appointed a commercially savvy chief executive to lead its transition to profitable growth. Annual results are due next Monday, and company guidance is for revenue of £58.7m, gross margin in excess of 67% (versus 62% in 2017), and year-end cash of not less than £25m.
There’ll still be a bottom-line loss at this stage, but I view a valuation of 4.4 times sales as attractive for a cashed-up company with strong growth prospects. Horizon’s management turned down a 181p a share takeover approach from Abcam last year, saying it “fundamentally undervalues” the business. I see the stock as a credible speculative buy.
Trek
Just added another 841 shares here so have built up a decent (for me) position now. Remember last raise at 2.05 and recent director buys together with upbeat guidance. I think HZD have turned a corner and revenues will be a beat. Trek, self conviction.
Going to hot up, that 2m sell has to be a buy as does the earlier 500k sell. Just look at the prices either side at same time. Matters not though as its volume and that’s the indicator we want. Trek.
Think you are spot on about the sp 15 sounds a good guess to me. Wish Abcam would make another move as I have both. Then if they zoom up a bit I could add to gsk. Abcam are greatly undervalued in my view.
I note that and the ask doesn’t even move. I suspect it’s been worked through a blinder by broker off recent falls. You watch the sp spike like 15p in a couple of days now for no apparent reason as they try and grab some stock back. £870k is some punt and we haven’t had any TR1s from our instis for ages now. Could be a new buyer. ABC would be nice as I need the money here to work harder once a decent profit is made as so many opportunities coming up. Trek from the sweet shop.
500,000 bought methinks it’s a fund,or could it be the beginnings of an Abcam raid ( wishful thinking Maybe) still future looks very good .
I agree and have added. Looking at tea leaves, Jayesh our new CFO is doing a webcast with the results. He’s keen to sell the news. We have had deals with Rutgers, C4X as well as the results from Dharmacon to now hit the bottom line. CRISPR has been in the news lately and seems to be the go to gene editing tool. Put Abcam in the mix, reading their finals they are looking to be more accretive as they are not growing fast enough organically and they now have more cash should they wish to come back to Hzd which imo would be after the finals.
Looking at our guidance it’s no wonder Jayesh wants to grab the limelight.....if we exceed these numbers 200 will be blown away and ABC will need to get a wiggle on if the want us.
“The Group also expects to report a significant expansion in gross margins to in excess of 67% (FY 2017: 62%) driven by portfolio optimisation of both products and services. Additionally, EBITDA before exceptional items is expected to be positive and ahead of market expectations. The Group cash balance of not less than £25 million is also well ahead of expectations, as a result of higher gross margins, cost discipline and a focus on debtor collection.”
Also note the ii’s seem to have settled now.
All imo but expecting fireworks.
Trek added 1468 as expecting a tick up now towards results.
Upped my holdings by 1775. Now looking forward to the next few weeks. Surely it must go up to 200 at least.
I’m upping my stake Monday. On the expectation of good figures end of April and deharmacon in its gene silencing area.
Noticed the news headline above concerning gene silencing drugs. Deharmacon also work in this field.
Out of close period and they buy, all below 150. Trek, on bargains!
All I could find was “£45million for genomics research at the European Bioinformatics Institute“ (Cambridge), HZD have supplied stem cells for them. Trek, perhaps the can buy new genes.
We may, just may see a lift from any increased R&D spend in the genetics space with universities and grants from the spring budget. Trek go on Hammond you helped build houses...
So after my post sp goes up on a 1 share trade. Not sure I agree with the code 1 scenarios although I do understand MMs get a pre RNS warning, more of a chaos management safeguard. There was also a 3 share trade. Usually these can be small divi trades on larger stocks or just system trades. They show on LSE. Anyways enough diatribe let’s see what chaos tomorrow brings. Disruptive Trek.
Looks like the sub 150 train has left the station. SP rise now on run up to results 29th April. Seems that so much money on AIM can’t sit in the same place for more than a week so expect a last minute surge. Good results = good defence, £2.80 - £3.00 T/O, indifferent results, just meeting guidance £2.50, may see two buyers then. But one thing I see as a given is results will be a min as guided. Abcam took a hit on good numbers because imo investors need to see growth, they have the cash and they can’t achieve it organically so what’s next. If Abcam can buy HZD both stocks may rise. Trek all imo DYOR £2.80, easiest trade on AIM if you got a few months.
Managed to get 766 at 146.85. Just a lucky sp dip then. Had to sell CSN to add. Will buy more later but sub 150 was too good to miss. Trek lucky dip!
From today’s RNS...”· Strong cash generated from operating activities of £36.4m (H1 2018: £32.9m), ending period with cash of £83.2m; £200m Revolving Credit Facility (RCF) signed post period end, providing additional flexibility as we continue to pursue attractive corporate transactions”
No they are out of close period I think things may not up here. What is annoying is HZD sp, went to 138 yet was 149 still to buy. I think when market gets sniff of abcams intentions we will be back towards 200. Trying to free funds now to add as could exit at 200 and let rest ride. Trader Trek. Lol!